Australia's S&P/ASX 200 slipped 0.3% to 8,153.20 ... which sank 6.3% amid concerns about two of the drug maker’s blockbuster ...

Australia’s S&P/ASX 200 slipped 0.3% to ... about two of the drug maker’s blockbuster products: diabetes treatment Mounjaro and weight loss counterpart Zepbound. Also falling was Trump Media ...

Lilly’s most popular products are its tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. However, sales of these drugs disappointed due to inventory issues ...

The company said sales of Mounjaro and Zepbound were hurt in the latest quarter by wholesalers cutting inventory, after they increased inventory at the end of the previous quarter. Tomi Kilgore is ...

Lilly’s stock has risen 53.6% so far this year compared with an increase of 17.1% for the Large Cap Pharmaceuticals industry. Mounjaro was launched in mid-2022, while Zepbound was launched in ...

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...

Eli Lilly stock (NYSE: LLY) will report its Q3 results ... All eyes will be on Eli Lilly’s diabetes drug – Mounjaro – and its weight-loss drug – Zepbound. In this note, we discuss the ...

Mounjaro and Zepbound’s big sales miss disappointed investors, causing the stock to plummet. Lilly’s stock has risen 55.0% so far this year compared with an increase of 17.6% for the industry.